Skip to main content

Novel Rx

Tapering Methotrexate with Biologics or JAK Inhibitors in RA Dr Segan ( @JulianSegan) discusses Abstract 0916 at #ACR22.https://t.co/CUjZ7SiSoE https://t.co/VYtmCIJEt6
Comparing Biosimilar Growth in the US, Germany, and Switzerland The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. https://t.co/LYcG0BNO6C https://t.co/V2m8HoIWLF
PSA2L.jpg

The Top 10 Research Priorities in Psoriatic Arthritis

Dec 06, 2022

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).



A series of surveys were initated by the British Psoriatic Arthritis Consortium (BritPACT) and funded by the James Lind Alliance (JLA

Read Article
cost.price_.biologic.injectable.jpg

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Dec 05, 2022

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow

Read Article
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/LH3MpT0o9O https://t.co/VeCbcdq5Ie
Low Dose IL-2 Therapy in Sjögren’s There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance. https… https://t.co/r0AlTD45gG
COVID.virus_.corona.jpg (keep)

Rheum Drugs & IDSA Guidelines to Treat COVID-19

Dec 01, 2022

The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

Read Article
infusion.biologic.jpg

RECITAL Trial: RTX vs. CTX in CTD-ILD

Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article
230px-Sjogren_syndrome_%282%29.jpg

Low Dose IL-2 Therapy in Sjögren’s

Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article
lupus SLE

Tyk2 Inhibition Effective in SLE

Nov 28, 2022

Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.



The results of this phase II trial were recently presented at ACR 2022. This  phase II multinational trial enrolled 363 adults with

Read Article
To Switch or Not: Biosimilars in Inflammatory Arthritis Dr. Jonathan Kay reports on abstract 1112 at #ACR22 Convergence. https://t.co/nrsH7yB7wu https://t.co/TngS4Kk6YK
scale decision balance question

The disconnect between objective inflammatory response and PROs in AxSpA

Nov 23, 2022

The assessment of disease activity in AxSpA involves the use of objective inflammatory response (OIR) and patient reported outcomes (PROs). In clinics, a combination of OIR and PROs are used to measure disease activity and response to treatment. OIR includes measurements such as CRP and MRI

Read Article
together solution

A Multidimensional Approach in the Management of Axial Spondylarthritis

Nov 21, 2022

There has been much focus on the pharmacologic management of axSpA. Despite optimal control of inflammation, symptoms of fatigue and pain can persist. Long term use of analgesics including opioids carries significant risks. Strategies to improve response to treatment in this population is

Read Article
lupus SLE

Dual target blockade may be better than one in SLE

Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus. However, outcomes of therapies within the same class (i.e. BAFF-inhibitor) when evaluated in randomised controlled trials have been inconsistent.

Read Article
Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients and improvement in quality of life. Sustained remission was 28.3% SAR vs 10.3% comparator arm. Spiera R Abs#1676 https://t.co/gXGJzbYLHK #ACR22 @RheumNow https://t.co/oZBsRtxMUw
#abst1679 #acr22 @rheumnow CARRA STOP-JIA early introduction of bDMARD beneficial in polyarticular JIA: in early combination of cDMARD+biologic group > pts able to achieve Clinical Remission& significantly longer T spent in CID& cJADAS10 ID during the 3 year study vs step up Rx https://t.co/xwQJnSeCNE
L05 #ACR22 High-dose Denosumab in Erosive Hand OA 48Wk, Double-blind PBO Phase 2 100 patients GUSS change higher in DEN v PBO at w24, incr at w48 New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001) Open label extension w improvement to baseline @RheumNow https://t.co/X6MF9q2bKj
Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW
Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz
In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO
Baker et al, Corevitas registry in 7000+ RA pts Pts w/ moderate pain HR 1.37 Pts w/ severe pain HR 1.42 more likely to switch to diff MOA b/tsDMARD Adjusted for confounders incl DA Time we address pain separately to spare MAOs in a lifelong disease! Abs#1590 #ACR22 @Rheumnow https://t.co/RP8Rb6bp9m
Goldman et al. RTX, TCZ in SSc ILD. 129 patients, 87 RTX, 32 TCZ, 10 both. Median changes in %FVC and %DLCO pre-and post-treatment were +0.35% and -0.8% for rituximab and -0.9% and +0.2% for tocilizumab. Majority stable/improved @RheumNow #ACR22 Abstr#1520 https://t.co/ydY5FGEYnQ https://t.co/O9QD7nkjdZ
Avouac @AvouacJerome et al. Maintaining complete B cell depletion assoc RTX efficacy in CTD-ILD. % with FVC improvement - 67% vs 50% for B cell depletion 1 year, 89% vs 50% B cell depletion last infusion. @RheumNow #ACR22 Abstr#1527 https://t.co/xr7DHOHci2 https://t.co/2n95PgzLxN
Sanchez Martin et al. Assessing effect tocilizumab by PET in GCA. Vascular involvement not generally fully controlled by tocilizumab. Not sure how PET was scored here. @RheumNow #ACR22 Abstr#1257 https://t.co/cGEoScnPb3 https://t.co/W0yYMPMjni
×